Slide 1 of 5 From SC Ray, MD, at Chicago, IL: May 20, 2013, IAS-USA. IAS–USA Stuart C. Ray, MD, FIDSA Professor of Medicine and Oncology Director, Infectious.

Slides:

Advertisements

Similar presentations

Hepatitis Studies Shyam Kottilil M.D., Ph.D.

Advertisements

Current Status and Benefits of Therapy for Chronic Hepatitis C Virus (HCV) Fuad AM Hasan Department Of Medicine Faculty of Medicine Kuwait University.

Future Trials of Hepatitis C Therapy in the HIV Co-infected Stephen D. Shafran, MD, FRCPC, FACP Department of Medicine, Division of Infectious Diseases.

Hepatitis C & HIV in 2011 Vincent Soriano Infectious Diseases Department Hospital Carlos III, Madrid, Spain.

Washington D.C., USA, July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.

The Hepatitis B&C Past and Present Martin J Spitz MD FACP AGAF Clinical Professor of Medicine UCSF.

Slide 1 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA David L. Wyles, MD Associate Professor of Medicine University of California.

Hepatitis web study Hepatitis web study Simeprevir in Genotype 1 (Viral Relapsers) PROMISE Trial Phase 3 Treatment Experienced Forns X, et al. Gastroenterology.

HCV resistance Understanding the mechanism and Prevention

Chris Fraser, MD Medical Director, Cool Aid Community Health Centre Clinical Faculty, UBC Faculty of Medicine.

Slide 1 of 13 From S Naggie, MD, at Washington, DC: June 18, 2013, IAS-USA. IAS–USA Susanna Naggie, MD Assistant Professor of Medicine Duke Clinical Research.

Direct Acting Antivirals: What are they

The new Treatments Dr John F Dillon. Curing one person Curing a population one person at a time.

N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER CROI 2015: What’s New in Hepatitis? Nina Kim, MD Associate Professor of Medicine Division of Allergy &

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-1 Phase 3 Treatment Naïve Source: Afdhal N, et al. N.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Phase 3 Treatment Experienced Source: Afdhal N, et.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT-1 and HIV Coinfection NIAID ERADICATE Trial Phase 2a Treatment Naïve and Treatment.

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV versus Interferon alfa-2b RIBAVIC STUDY Phase 3 Treatment Naïve, Chronic HCV and HIV.

Hepatitis web study Hepatitis web study PEG alfa-2a + RBV versus PEG alfa-2a versus INF + RBV APRICOT STUDY Phase 3 Treatment Naïve, Chronic HCV and HIV.

The Future: Is Ribavirin Still Useful? David Nelson, MD Professor of Medicine, Microbiology, and Molecular Genetics Associate Dean, Clinical Research and.

Hepatitis web study Hepatitis web study Sofosbuvir-Ledipasvir +/- Ribavirin in GT-1 LONESTAR Trial Phase 2a Treatment Naïve and Treatment Experienced Source:

Hepatitis web study Hepatitis web study Sofosbuvir in HCV-HIV Coinfection & HCV GT 1,2,3 PHOTON-1 Trial Phase 3 Sulkowski MS, et al. JAMA. 2014;312:

Ledipasvir-Sofosbuvir (Harvoni)

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in Treatment-Experienced GT1 with Cirrhosis SIRIUS Phase 2 Treatment Experienced Bourliere.

Controversies: Lead in or no lead in ? PRO Controversies: Lead in or no lead in ? PRO Lawrence Serfaty Hôpital Saint-Antoine Paris 5th Paris Hepatitis.

Slide 1 of 8 From MG Peters, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor.

Management of Patients Co- infected with HCV and HIV: A Close Look at the Role for DAAs Susanna Naggie, MD Assistant Professor of Medicine Division of.

Predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin Paul Y Kwo, MD Professor of Medicine Medical Director,

Update on the HCV Antiviral Pipeline Todd S. Wills, MD SPNS HCV Treatment Expansion Initiative Evaluation and Technical Assistance Center Infectious Disease.

Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.

ELECTRON  Design SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ELECTRON Study: SOF-based therapy for genotypes 1, 2 and 3 W8W4W12 ≥ 19 years Chronic.

OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.

Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Treatment of Chronic HCV Genotype 5 or 6 Robert G. Gish MD Staff Physician, Stanford University.

NS5A and polymerase inhibitors Mark Sulkowski, MD Professor of Medicine Johns Hopkins University Baltimore Maryland

AI Study  Design SOF 1W then DCV + SOF 23W DVC + SOF Randomisation* 1 : 1 : 1 Open-label AI Study: DCV + SOF + RBV for genotypes 1, 2 and.

How to avoid a resistance issue with the first generation protease inhibitors ? O. Lada PHD Service d’Hépatologie et INSERM CRB3, AP-HP Hopital Beaujon,

SIRIUS Placebo LDV/SOF + placebo Randomisation* 1 : 1 Double-blind SIRIUS Study: LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior.

Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.

Lead in – or NOT? Graham R Foster Professor of Hepatology Queen Marys University of London.

Hepatitis C Nonresponders

BOCEPREVIR & TELAPREVIR

Forns X. J Hepatology 2015; 63: C-SALVAGE Study: grazoprevir + elbasvir + RBV in genotype 1 with failure to PI-based regimen –NS3 and NS5A RAVs.

David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California State of the Art in Hepatitis C Virus Infection.

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 AI Trial Phase 2a Treatment-Naïve and Treatment-Experienced.

Hepatitis web study Hepatitis web study Simeprevir versus Telaprevir with PR in GT1 ATTAIN Trial Phase 3 Treatment Experienced Reddy KR, et al. Lancet.

ELPA Symposium Compassionate Use in Hepatitis C Saving lives of patients who cannot wait Thomas Berg Section of Hepatology Clinic for Gastroenterology.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIH SYNERGY Phase 2 Treatment Naïve (unfavorable baseline.

The new Treatments The old problem Dr John F Dillon.

Nancy Reau, MD University of Chicago Chicago, Illinois Mark S. Sulkowski, MD Johns Hopkins University School of Medicine Baltimore, Maryland Clinical Outcomes.

Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health University of Alabama at Birmingham Birmingham, Alabama Cases From the Clinic(ians):

EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis.

Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial

Future Trials of Hepatitis C Therapy in the HIV Co-infected

Phase 2 Treatment Naïve HIV Coinfection

HIV/HCV Co-Infection Case

DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?

Resistance to Direct Acting Antiviral Therapy

Case 53-year-old Black Man

Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals Susanna Naggie, Mark S. Sulkowski Gastroenterology

Simeprevir in HIV Coinfection, GT-1 C212 Trial

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

Hepatitis C in the HIV-infected patient

Phase 3 Treatment Naïve and Treatment Experienced HIV Coinfection

New HCV therapies on the horizon

What Does the Future Hold and What Will It Mean for Patients?

Telaprevir in Treatment Experienced GT-1 PROVE3

Telaprevir + Peginterferon + Ribavirin for GT1 PROVE1 Study

Presentation transcript:

Slide 1 of 5 From SC Ray, MD, at Chicago, IL: May 20, 2013, IAS-USA. IAS–USA Stuart C. Ray, MD, FIDSA Professor of Medicine and Oncology Director, Infectious Diseases Fellowship Program The Johns Hopkins University School of Medicine Baltimore, Maryland Hepatitis C Virus (HCV) Coinfection: Don’t Stand Still Just Because the Landscape Looks Better From SC Ray, MD, at Chicago, IL: May 20, 2013, IAS-USA.

Slide 2 of 5 From SC Ray, MD, at Chicago, IL: May 20, 2013, IAS-USA. HCV DAA Glossary Generic nameCode nameClass sovaprevirACH-1625PI setrobuvirANA598NNI faldaprevirBI PI daclatasvirBMS NS5A asunaprevirBMS PI ledipasvirGS-5885NS5A sofosbuvirGS-7977Nuc vaniprevirMK-7009PI mericitabineRG 7128Nuc danoprevirRG 7227PI boceprevirSCH PI simeprevirTMC435PI telaprevirVX-950PI

Slide 3 of 5 From SC Ray, MD, at Chicago, IL: May 20, 2013, IAS-USA. DAA Regimens in Phase 3 Trials PINS5ANon- nucleoside polymerase Nucleo(t)ide polymerase RibavirinPegIFN SofosbuvirRBV+/- PegIFN alfa LedipasvirSofosbuvir+/- RBV ABT50/rABT267ABT333+/- RBV AsunaprevirDaclatasvir+/- RBV+/- PegIFN alfa SimeprevirRBVPegIFN alfa FaldaprevirRBVPegIFN alfa VaniprevirRBVPegIFN alfa Faldaprevir*BI7127RBV DaclatasvirRBVPegIFN lambda *Subgenotype 1b only

Slide 4 of 5 From SC Ray, MD, at Chicago, IL: May 20, 2013, IAS-USA. Telaprevir Added to P+R in patients with HIV and HCV-1 Sulkowski MS, et al. NEJM 2013

Slide 5 of 5 From SC Ray, MD, at Chicago, IL: May 20, 2013, IAS-USA. Resistance: Common Themes and Some Differences Nonsuppressive therapy generates resistance Combination therapy: – Reduces risk of resistance with HIV and HCV – Not required for HBV (monotherapy is effective) For HIV and HBV, resistance is “permanent” – Not known for HCV